Annual Report 2017
Department of Pharmacy
Hiroyuki Terakado
Introduction
The Department of Pharmacy stores and dispenses drugs, prepares injections (including aseptic mixtures), collects and disseminates drug information, and provides patients with guidance regarding the proper use of drugs. Its services have been improved toward the hospital's goal of envisaging the highest quality of medical care, practice, and research. A state-of-the-art computerized system and other pharmacy-related equipment ensure quality control and inventory management, promote the proper use of drugs, and enhance the efficiency and quality of our services.
Our team and what we do
As part of the fundamental function of the hospital, the Department of Pharmacy prepares and dispenses oral and topical medicines and injections for individual patients. All outpatients and inpatients are provided with aseptic mixtures of injectable chemotherapy agents prepared in our department. As the importance of providing drug information for patients has been widely acknowledged, clinical pharmacists visit inpatients and give advice on taking medicine, focusing especially on pain control with opioids, and participate in the palliative-care support team, while our department provides outpatients with guidance on the proper use of opioids and anti-cancer agents. Our department also places pharmacists in every hospital ward to provide medication reconciliation services for inpatients, with a view to enhance the quality of chemotherapy as well as to ease burdens on doctors and nurses.
Pharmacists collect, compile, and maintain a database of drug information and distribute pertinent information to the medical staff. Drug information is disseminated quickly throughout the hospital by paper distribution and/or on the in-hospital computer network. Pharmacists individualize dosage regimens for specified drugs such as tacrolimus, aminoglycosides, and vancomycin based on both measured blood concentrations and pharmacokinetic analysis to maximize their efficacy, and to minimize adverse events.
A physician places an order through the hospital's computerized electric medical record system. The prescription order is then redirected to the medicine-package-printing system which provides drug information. The medicine-package
information, instructions and explanations, which are easy to understand for patients, for the proper use of drugs, such as those regarding efficacy and effectiveness, precautions, and guidance concerning symptoms in the early stage of adverse reactions, are automatically printed out for patients when a prescription is ordered.
The injection-order is directly linked to an automatic "picking system" device, and this linkage ensures that injections are made properly and efficiently. This injection-ordering system contains an additional function which is a regimen-ordering system for anti-cancer drugs that makes it possible to check the dose as well as the interval of chemotherapy. The Department of Pharmacy also has a robot which prepares injection preparations without human assistance.
Research activities
Since an important mission of the Department of Pharmacy is to contribute to the development of new drugs, inventory control, and handling of new investigative drugs are performed in accordance with Good Clinical Practice
regulations. Research on the safety management of chemotherapy is conducted including handling of chemotherapeutic drugs, reduction of incidents regarding drugs, and improvement of pain control for patients who need palliative care through the use of guidance materials. A couple of studies on the pharmacokinetics and pharmacodynamics of cancer-related drugs have been performed and some of the results have been reported in international conferences and journals.
Table 1. Number of Prescriptions in 2017
Table 2. Amounts of Drugs Consumed in 2017
Table 3. Aseptic Preparation of Injectable Drugs in 2017
Table 4. Investigational Drugs
Education
The National Cancer Center Hospital (NCCH) offers a three-year postgraduate pharmacy residency training in clinical oncology. In the first year, the program places the most importance on the technical aspects of cancer care. In the second year, through required rotations in a variety of focused hematology/oncology services, residents will refine their clinical problem-solving skills in cancer management and patient education, as well as provide pharmaceutical care to ambulatory care patients and participate in an oncology-focused Drug Information Program. In the third year, residents participate in specialized pharmaco-clinical practice and research activities, which may be tailored to residents' goals. The NCCH also provides a two-year chief residency program in which post-residency trainees may develop their clinical research capabilities to a higher level. Moreover, there are opportunities for educational activities, such as a training course for visiting expert pharmacists and post-graduate students of pharmacy, and participation in a multi-institutional TV conference.
Future prospects
In order to provide the best cancer care, the Department of Pharmacy promotes "offering the best cancer treatments", "developing and spreading new treatments", "educating young pharmacists for oncology", and "providing information both in and outside Japan".
List of papers published in January 2017 - March 2018
Journal
1. Ebata T, Yunokawa M, Yoshida H, Bun S, Shimoi T, Shimomura A, Kodaira M, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Tamura K. The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma. Int J Gynecol Cancer, 27:1850-1855, 2017
2. Hanazawa T, Asayama K, Watabe D, Hosaka M, Satoh M, Yasui D, Obara T, Inoue R, Metoki H, Kikuya M, Imai Y, Ohkubo T. Seasonal variation in self-measured home blood pressure among patients on antihypertensive medications: HOMED-BP study. Hypertens Res, 40:284-290, 2017
3. Hosaka M, Inoue R, Satoh M, Watabe D, Hanazawa T, Ohkubo T, Asayama K, Obara T, Imai Y. Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients. Clin Exp Hypertens, 1-8, 2017
4. Iizumi S, Shimoi T, Tsushita N, Bun S, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study. BMC Cancer, 17:819, 2017
5. Makita S, Munakata W, Watabe D, Maeshima AM, Taniguchi H, Toyoda K, Yamauchi N, Fukuhara S, Maruyama D, Kobayashi Y, Tobinai K. Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome. J Int Med Res, 45:886-893, 2017
6. Tanabe A, Asayama K, Hanazawa T, Watabe D, Nomura K, Okamura T, Ohkubo T, Imai Y. Left ventricular hypertrophy by electrocardiogram as a predictor of success in home blood pressure control: HOMED-BP study. Hypertens Res, 40:504-510, 2017
7. Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol, 23:382-388, 2018
8. Bun S, Yonemori K, Akagi T, Noguchi E, Shimoi T, Shimomura A, Yunokawa M, Shimizu C, Fujiwara Y, Makino Y, Hayashi Y, Tamura K. Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. Invest New Drugs, 36:151-155, 2018
9. Bun S, Yunokawa M, Tamaki Y, Shimomura A, Shimoi T, Kodaira M, Shimizu C, Yonemori K, Fujiwara Y, Makino Y, Terakado H, Tamura K. Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer. Support Care Cancer, 26:2161-2166, 2018